Hypothesis

Transient epigenetic priming of adult mesenchymal stem cells (MSCs) with a short pulse of OCT4, SOX2, and KLF4 (OSK) enhances their secretome and extracellular vesicle (EV) cargo, thereby improving immunomodulation and reducing tumorigenic potential when transplanted into the aged brain, outperforming both naïve MSCs and iPSC‑derived neural progenitors.

Rationale

Recent work shows iPSCs rival ESCs in pluripotency but carry tumorigenic risk, while adult MSCs have low teratoma formation but limited regenerative potency 1. Perinatal stem cells bridge these traits 2. The regenerative capacity depends on microenvironmental signaling 3. We hypothesize that a brief, controlled expression of pluripotency factors reprograms MSC epigenetics without full pluripotency, boosting paracrine factors (e.g., TSG‑6, PGE2, miR‑146a) and loading EVs with neuroprotective miRNAs, thereby augmenting immune modulation and reducing off‑target proliferation.

Predictions

1. Primed MSCs will secrete higher levels of anti‑inflammatory cytokines and EVs enriched for miR‑124 and miR‑126 compared with naïve MSCs and iPSC‑derived neural progenitors.
2. In aged mouse models of neuroinflammation, primed MSC transplants will reduce microglial activation (Iba1+ area) and improve cognitive performance (Morris water maze) more effectively than naïve MSCs or iPSC‑derived neurons.
3. Primed MSCs will show no increase in teratoma formation or ectopic proliferation versus naïve MSCs, while iPSC‑derived grafts retain a measurable tumorigenic risk.

Experimental Design

• Isolate bone‑marrow MSCs from young adult donors.
• Transduce with a doxycycline‑inducible OSK cassette; administer doxycycline for 24 h to achieve transient expression, then withdraw.
• Validate epigenetic changes (ATAC‑seq for chromatin openness at pluripotency loci) and confirm absence of OCT4 protein after withdrawal.
• Collect conditioned medium and EVs; quantify cytokines (ELISA) and miRNA cargo (small‑RNA seq).
• Transplant equal cell counts (1×10⁵) into the hippocampus of 20‑month‑old LPS‑treated mice (n=10/group). Groups: (1) naïve MSC, (2) OSK‑primed MSC, (3) iPSC‑derived neural progenitor, (4) vehicle.
• Assess at 4 weeks: immunohistochemistry for Iba1, NeuN, and Ki67; behavior tests; MRI for graft survival; histology for teratoma markers.

Potential Outcomes & Falsifiability

If primed MSCs fail to increase anti‑inflammatory secretome or show no functional advantage over naïve MSCs, the hypothesis is falsified. Conversely, detection of teratoma formation in primed MSCs would falsify the safety claim. Demonstrated superiority in immunomodulation and cognition without tumorigenicity would support the hypothesis and suggest that controlled, transient reprogramming can convert adult stem cells into a superior therapeutic platform, challenging the view that iPSCs or ESCs are inherently better for regenerative neurology.